Cargando…

Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study

BACKGROUND: Rh-endostatin is a potent inhibitor of angiogenesis approved and widely used for advanced non-small cell lung cancer (NSCLC) in China. While the efficacy and safety of extended use of rh-endostatin with platinum-based chemotherapy during induced and maintenance therapy are still not very...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jing, Cheng, Yi, He, Liting, Wang, Jianhua, Xi, Qingsong, Gong, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745542/ https://www.ncbi.nlm.nih.gov/pubmed/36524068 http://dx.doi.org/10.21037/jtd-22-1292

Ejemplares similares

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study
por: Pu, Xingxiang, et al.
Publicado: (2022)

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Yuan, Meng, et al.
Publicado: (2021)

Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study
por: Yu, Xun, et al.
Publicado: (2018)

Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer
por: Biaoxue, Rong, et al.
Publicado: (2012)

Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases
por: Zhou, Yunzhi, et al.
Publicado: (2021)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Endostar (rh‐endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: An, Jihong, et al.
Publicado: (2018)

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma
por: Li, Yuan, et al.
Publicado: (2019)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study
por: Xu, Hairong, et al.
Publicado: (2019)

Combined BRM270 and endostatin inhibit relapse of NSCLC while suppressing lung cancer stem cell proliferation induced by endostatin
por: Gu, Yan-hui, et al.
Publicado: (2021)

Endostatin in the pancreas
por: Wigmore, S J
Publicado: (2005)

Antiangiogenic effects of recombinant human endostatin in lung cancers
por: He, Lang, et al.
Publicado: (2018)

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
por: Chen, Jianghao, et al.
Publicado: (2013)

Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer
por: Lv, Weize, et al.
Publicado: (2022)

Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis
por: Wang, Cheng-Qiong, et al.
Publicado: (2021)

Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer
por: Cunningham, Charnay, et al.
Publicado: (2023)

Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
por: Wang, Shan, et al.
Publicado: (2016)

Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis
por: Feng, Li, et al.
Publicado: (2021)

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
por: Bachelot, T, et al.
Publicado: (2006)

Dynamic Contrast-Enhanced MR Imaging in a Phase Ⅱ Study on Neoadjuvant Chemotherapy Combining Rh-Endostatin with Docetaxel and Epirubicin for Locally Advanced Breast Cancer
por: Jia, Qianxin, et al.
Publicado: (2012)

A new path for endostatin
por: Dove, Alan W.
Publicado: (2002)

A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer
por: Sun, Xiao-Jiang, et al.
Publicado: (2016)

Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer
por: Zhang, Li, et al.
Publicado: (2022)

The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer
por: Liu, Yanyang, et al.
Publicado: (2016)

In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma
por: Xie, Fang, et al.
Publicado: (2017)

Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis
por: Zhang, Shu-Ling, et al.
Publicado: (2020)

Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model
por: Ding, Rui-Lin, et al.
Publicado: (2017)

Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization model
por: Ge, Hong-yan, et al.
Publicado: (2011)

Effects of lentivirus-mediated endostatin on endothelial progenitor cells
por: Ai, Jing, et al.
Publicado: (2017)

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer
por: Chen, Chong, et al.
Publicado: (2020)

Endostatin in fibrosis and as a potential candidate of anti-fibrotic therapy
por: Zhang, Zequn, et al.
Publicado: (2021)

Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study
por: Ge, Jing-jing, et al.
Publicado: (2020)

Real‐world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non‐driver gene mutation advanced non‐small cell lung cancer
por: Wang, Zhongtai, et al.
Publicado: (2019)

Effect of endostatin overexpression on angiotensin II-induced cardiac hypertrophy in rats
por: Dai, You-Jin, et al.
Publicado: (2019)

Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer
por: Fu, Weijiang, et al.
Publicado: (2017)

Improving the therapeutic potential of endostatin by fusing it with the BAX BH3 death domain
por: Chura-Chambi, R M, et al.
Publicado: (2014)

Endostatin expression in pancreatic tissue is modulated by elastase
por: Brammer, R D, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_gdap3tcca8oovkgghd7lk0csno